Form D · Pharmaceuticals

Aeovian Pharmaceuticals, Inc.

Berkeley, CA · CIK 0001710088

Offering snapshot reported Dec 22, 2025 · SEC filing

Reported sold
$55M
Offering amount: $55M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 18, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 22, 2025Initial$54,999,996No comparison13SEC filing
May 13, 2024Initial$50,415,077No comparison5SEC filing
Oct 9, 2019Initial$18,799,907No comparison5SEC filing
Jun 28, 2017Initial$785,687No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-567748

Source: Form D, filed Dec 22, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Youssef Bennani Director
Jens Eckstein Director
Lars Ekm Director
Lars Ekman Director
Richard Gaster Director
Justin Gover Director
William Greene Director
Allison J. Hulme Director, Executive
Themasap Khan Director
John Kincaid Executive
David Lowe Director
Ian Massey Executive
James Peyer Director
Matthew J. Plunkett Executive
Michael Powell Director
Nils Regge Director
Davis Ryman Executive
Stelios Tzannis Director, Executive
Ben Zadik Executive
Micah Zajic Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2930 Domingo Ave., Suite 145
Berkeley, CA, 94705